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ABSTRACT 
Objectives: The aim of this study was to assess the effects of non-surgical periodontal treatment on 
gingival crevicular fluid (GCF) cytokines in patients with generalized aggressive periodontitis 
(GAgP), in relation to clinical parameters. 
Materials and Methods: Data were obtained from 16 GAgP patients and 15 periodontally healthy 
controls. Periodontal parameters and GCF biomarker levels were evaluated at baseline, and repeated 3 
and 6 months after treatment for GAgP subjects. Moderate and deep pocket sites were analysed 
separately. The amount of interleukin (IL)-1β, IL-9, tumor necrosis factor (TNF)-, platelet-derived 
growth factor (PDGF-bb) and vascular endothelial growth factor (VEGF) were measured using a 
highly specific and sensitive multiplex bead immunoassay. 
Results: At baseline cytokine levels in the moderate and deep pocket sites of GAgP patients were 
higher than those of the healthy control sites. In GAgP group periodontal treatment led to 
improvement in all examined clinical parameters and resulted in a statistically significant reduction in 
the total amounts of IL-1β, VEGF, and TNF-, in comparison to baseline, already 3 months after 
therapy in both moderate and deep pocket sites and of PDGF-bb in deep sites (p < 0.01). At the 
concentration level, only IL-1β and VEGF were affected.  
Conclusion: Non-surgical treatment of GAgP provided significant clinical benefits leading to a 
marked decrease in the GCF levels of some pro-inflammatory and pro-angiogenic cytokines, but not 
of IL-9 and PDGF-bb.  
Clinical relevance: Although the periodontal therapy successfully decreased clinical signs of 
inflammation, the GCF levels of some inflammatory cytokines were still elevated.  
Keywords: aggressive periodontitis; gingival crevicular fluid; inflammatory mediators; 
periodontal/therapy. 
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Introduction 
Generalized aggressive periodontitis (GAgP) has a complex pathogenesis in which a particular host 
response to the long term microbial challenge has been proposed to contribute to its clinical 
manifestations in terms of disease onset and progression rate [1]. As such, beyond genetic 
characteristics [2] and functional defects of polymorphonuclear leukocytes [3], previous studies have 
considered the periodontal levels of inflammatory mediators that may be involved in protective and 
damaging reactions to periodontal pathogens [4, 5]. A noninvasive approach to monitor the local host 
response involves analysis of such biomarkers in the gingival crevicular fluid (GCF) [6]. There is 
increasing evidence that patients with GAgP have higher GCF concentrations of inflammatory 
markers compared to healthy control subjects [7-9], but it is not clear whether they share similar 
cytokine profile to chronic periodontitis patients [10]. Unlike data for classic markers such as 
interleukin (IL)-1ß, IL-6, IL-8 and tumor necrosis factor (TNF)-, there is no or little evidence 
regarding the GCF levels of mediators involved in angiogenesis and in modulation of 
inflammatory/immune response before and after periodontal treatment [11-14]. Angiogenesis is a 
prominent feature of inflammation and healing, but its role in promoting the progression of 
periodontal lesions is not yet clear [15]. Vascular endothelial growth factor (VEGF) is a 
multifunctional cytokine that plays a pivotal role during inflammation by mediating 
neovascularization [16]. There is considerable evidence that VEGF increases micro-vascular 
permeability, stimulates endothelial cell proliferation, and induces proteolytic enzymes and migration 
of endothelial cells and monocytes [17]. In recent years, the possible role of VEGF in the pathogenesis 
of chronic periodontitis has been investigated in some clinical studies with conflicting results [18-20]. 
Platelet-derived growth factor (PDGF) is another key mediator for vascular development and is one of 
the most potent serum mitogens. It promotes cell migration and proliferation and stimulates fibroblasts 
to synthetize collagen and proteoglycans [21]. While VEGF initiates endothelial cell proliferation and 
blood vessel formation, PDGF is an important growth factor for maturation and remodeling of newly 
formed blood vessels [22]. VEGF expression is regulated by IL-1 and TNF-α, which are primary 
mediators in the early inflammatory response and are able to induce tissue destruction and bone loss in 
periodontal diseases [23]. These cytokines induce vascular alterations and prompt migration to the 
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periodontium of different cells, e.g. neutrophils [24, 25], and are involved in T-helper type 1 (Th1) 
cells immune response [26].  
Recently, Th9 cells were discovered and shown to interact with the Th1 subpopulation in the 
modulation of inflammatory/immune responses [27]. Th9 cells characteristically produce IL-9, which 
can exert anti-inflammatory activities by modulating IL-1 and TNF-α production [28]. Previous 
investigations demonstrated that IL-9 is expressed in both human granulomas and animal experimental 
periapical lesions as it is related to the lesion stability [29, 30]. Apart from one study analyzing the IL-
9 serum levels in chronic periodontitis patients, no data are available on its role in periodontal diseases 
[31].  
In our hypothesis, the higher GCF concentrations of inflammatory mediators observed in patients 
suffering from GAgP should be reduced after periodontal treatment, as well as those of angiogenic 
mediators. Anyhow, the relationship between cytokine profiles and clinical state of periodontal sites 
has not yet been clarified in patients suffering from GAgP [12,13,32]. Therefore, the aim of the 
present study was to determine whether non-surgical periodontal treatment for GAgP would change 
the GCF levels of cytokines involved in angiogenesis and inflammatory pathways. The treatment 
effects on GCF level of IL-1, IL-9, TNF-, PDGF-bb and VEGF in GAgP patients were examined in 
relation to the severity of initial periodontal damage and compared to periodontally healthy controls. 
Material and methods 
Study design 
The GAgP and periodontally healthy subjects participating in the study were consecutively recruited 
from a pool of first time patients at the Section of Periodontology, C.I.R. Dental School, Department 
of Surgical Sciences, University of Turin (Italy). The study was conducted between May 2015 and 
February 2017 in accordance with the Helsinki Declaration of 1975, as revised in 2002 and was 
approved by the local Ethics Committee (Protocol n° 0119237). Informed consent was obtained from 
each patient before the study.  
GAgP patients were Caucasians and were aged between 18 and 35 years. The diagnosis of GAgP was 
done according to the clinical and radiographic criteria by the 1999 classification of GAgP [33] and 
required familiar aggregation (during the anamneses patients were asked whether they had at least one 
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member of the family presenting or with a history of periodontal disease) [14]. They were also 
required to have at least 20 natural teeth and to demonstrate a minimum of 12 teeth with probing depth 
(PD) and clinical attachment level (CAL) ≥ 5 mm, and radiographic evidence of alveolar bone loss. At 
least six teeth apart from first molars or incisors had to be involved [14].  
To be included in the study, the periodontally healthy subjects had to be systemically healthy, have no 
PD and CAL >3 mm, less than 15% of the sites with bleeding on probing (BoP), and no horizontal or 
vertical bone loss in radiographic examination. 
Exclusion criteria for the two groups were: pregnancy, lactation, current or past smoking, allergy, 
asthma, periodontal treatment or/and antibiotic therapies in the previous 6 months, and any systemic 
disease that could influence the course of periodontal disease. Subjects using anti-inflammatory and 
immunosuppressive medications, or any other medications known to affect periodontal status were 
also excluded.  
Sample size calculation 
The change in VEGF levels after non-surgical periodontal treatment was set as the primary outcome. 
The sample size was calculated using variations reported for total amount of VEGF in chronic 
periodontitis patients [20] and an expected effect size. The minumum expected difference was 
assumed to be 6.0 pg/ml and the amount of variation reported was 10.9 pg. Therefore, at 0.05 two-
sided alpha error and 80% power, the calculated sample size was 14 GAgP patients for this paired trial 
that increased to 16 for compensation of possible dropout.   
Clinical Examination and Periodontal Treatment  
All enrolled subjects underwent periodontal examination by an experienced periodontist (F.R.). After 
calibration, a 94.8% concordance within 1 mm for measurements of PD and CAL between the first 
and the second recording with an interval of 24 h was reached. Clinical measurements were taken at 
six sites per tooth of every tooth present, except third molars, with a standardized periodontal probe 
(PCP UNC15, Hu-Friedy, Chicago, IL, USA) and included presence of plaque (PI), BoP, gingival 
index (GI) [34], PD, and CAL. Full-mouth percentage of sites with PI (full-mouth plaque score, 
FMPS) and BoP (full-mouth bleeding score, FMBS) was also recorded. Full-mouth periapical 
radiographs were taken with the long cone paralleling using Rinn holders. 
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After baseline examination, all GAgP subjects underwent a session of supragingival scaling and 
polishing and received instructions in proper self-performed plaque control measures, including 
instructions in the Bass technique and interproximal cleaning with dental floss and interdental brushes. 
One week later, patients were subjected to quadrant-wise full-mouth subgingival scaling and root 
planing (SRP) in four sessions by two experienced dental hygienists (L.Bi. and L.Bo.) using hand 
instruments (Gracey curettes, Hu-Friedy, Chicago, IL, USA) and ultrasonic scalers (Cavitron Select, 
Dentsply, York, PA, USA). Subgingival instrumentation was performed under local anaesthesia 
without a time limit until the root surface felt smooth and clean to an explorer tip. The entire non-
surgical periodontal treatment was completed in 28 days without the administration of local and/or 
systemic antimicrobials. Supportive therapy, including professional plaque control and reinstruction of 
oral hygiene was performed on a 2-week interval during the first 6 weeks postoperatively and every 2 
months up to the 6-month evaluation. Reevaluations were performed 3 and 6 months after completion 
of SRP procedure.  
GCF sampling 
The gingival crevicular fluid (GCF) samples were collected on the following day the clinical 
examination to prevent their contamination with blood due to probing of inflamed sites. Two inflamed 
moderate (sites with redness or BoP, PD 4-5 mm) and deep sites (sites with BoP, PD ≥ 6 mm) with no 
endodontic involvement were selected on the mesial aspect of anterior periodontally involved teeth in 
contralateral quadrants in GAgP patients. The same sites were sampled at baseline, 3 and 6 months 
after treatment. In the healthy control group two sites with absence of plaque and inflammation were 
sampled on the mesiobuccal aspect of anterior teeth.  
Sites to be sampled were isolated with cotton rolls and supragingival plaque was carefully removed. 
After the sites were gently dried with air syringe, GCF samples were collected with paper strips 
(PerioPaper Strips, Oraflow Inc., Plainview, NY, USA) that were inserted into the pocket until mild 
resistance was felt and then allowed to remain there for 30 s. Strips contaminated by bleeding were 
discarded. The amount of collected GCF was measured using an electronic device Periotron 8000 
(Oraflow Inc., Plainview, NY, USA), which was calibrated based on a protocol described before [35]. 
The readings from the electronic instrument were converted to an actual volume (l) by reference to 
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the standard curve. Throughout the experimental period, the reliability of the calibration of the device 
was checked at periodic intervals and, when necessary, it was renewed by triplicate readings. All strips 
with GCF were placed separately into coded sealed eppendorf microcentrifuge tubes containing 100 µl 
of sterile phosphate-buffered saline (PBS) and stored at -80°C until processing. 
Multiplex bead immunoassay 
IL-1β, TNF-α, IL-9, PDFG-bb, and VEGF concentrations were detected in biological samples by 
means of a high-sensibility Bio-Plex Suspension Array System (Bio-Rad Laboratories S.r.l., Segrate, 
Milan, Italy) according to the manufacturer’s instructions. Briefly, opportune anticytokine antibody-
conjugated beads were loaded into individual wells of a 96-well plate. After washing, standards and 
GCF undiluted samples were added into respective wells and incubated 30 min. After plates were 
washed, biotin-conjugated detection antibody was added. After another 30 min of incubation and 
consequent washing, streptavidin-conjugated PE was added for 10 min. After an additional wash, the 
complex was solubilized by adding the Bio-Plex assay buffer to each well. Then, plates were analyzed 
with the Bio-Plex Suspension Array System. Total amounts (pg) and concentrations (pg/l) of each 
cytokine were determined.   
Statistical analysis 
A statistical software program (Graphpad Prism version 6.0e, GraphPad Software, San Diego, CA, 
USA) was used for data analysis. The primary outcome measure of the study was mean reduction in 
VEGF levels after therapy. Secondary outcomes included changes of GCF levels of IL-1, IL-9, TNF-
, PDGF-bb as well as changes in clinical parameters. Only clinical measurements at the GCF 
sampling sites (experimental sites) were included in the present calculations. The mean values for each 
clinical and cytokine parameter was then calculated for each subject and averaged across subjects at 
each time points separately. 
The Shapiro–Wilk test and Q-Q normality plots were applied to verify the normal distribution of the 
continuous variables. The significance of changes in clinical data with time in moderate and deep 
pocket sites was determined using the repeated measures ANOVA (PD, CAL, GCF volume) or the 
Friedman test (PI, GI). Pairwise multiple comparisons were performed by the Tukey test or the 
Bonferroni corrected Wilcoxon signed rank test.  
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Changes in cytokine concentration and total amount through the follow-up period in different PDs in 
the GAgP and healthy control groups were evaluated by means of the ANOVA test followed by the 
post hoc Tukey test. The statistical significance of correlations between clinical parameters and 
biomarkers was determined using the Pearson and Spearman correlation test as appropriate. P values < 
0.05 were considered statistically significant. 
Results 
Twenty-six GAgP patients and twenty-two control subjects were consecutively screened for 
enrolment. Fourteen patients did not meet the inclusion criteria and three patients did not attend the 
baseline examination. Sixteen GAgP subjects (nine males and seven females, mean age 32.3 ± 4.3 yrs) 
were enrolled and completed the trial. The control group included six males and nine females with a 
mean age of 30.2 ± 6.1 yrs.  
Clinical parameters of the experimental sites selected for GCF sampling in GAgP and healthy controls 
are presented in Table 1. As expected, mean values of all periodontal parameters were significantly 
higher in GAgP than in control sites (p < 0.001).  
The postoperative healing was uneventful in all GAgP cases. No complications, such as abscess or 
infection, were observed throughout the study. Plaque level, presence and severity of inflammation, 
mean PD and mean CAL improved at 3 and 6 months after periodontal treatment (p < 0.001) in both 
moderate and deep pocket sites. PD reduction and CAL gain were significantly greater at deep sites at 
both 3- and 6-month examination (p < 0.001). Periodontal treatment was also associated with a 
statistically significant reduction in mean GCF volumes that was more pronounced in deep sites (p < 
0.001).  
As reported in Table 2, mean FMPS and FMBS decreased in GAgP group from baseline to 6 months 
(p < 0.001). At 3 and 6 months after therapy, no statistically significant differences were observed for 
FMPS values for the two groups.  
Significant differences were detected over time in IL-1 (Fig. 1) and VEGF (Fig. 2) concentration and 
total amount in the GAgP group with a different trend according to the baseline PD values. Both 
cytokines had significantly lower concentration at deep sites already 3 months after the non-surgical 
treatment (p < 0.05), whereas at moderate sites, a statistically significant decrease was observed after 6 
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months (p < 0.001 IL-1 and p < 0.05 VEGF, respectively) (Fig. 1A and Fig. 2A). Furthermore, the 
concomitant reduction in GCF volumes induced a significant decrease (p < 0.001) of IL-1 (Fig. 1B) 
and VEGF (Fig. 2B) collectable picograms already after 3 months at both moderate and deep pocket 
sites. 
A transient increment in IL-9 concentration was detected at moderate sites at 3 months postoperatively 
(p < 0.05), but concentration lowered until reached not significant differences with respect to baseline 
values at 6 months (Fig. 3A). No significant changes were detected considering the total amounts of 
this cytokine (Fig. 3B).  
On the contrary, despite no differences were detected in GCF concentrations of PDGF-bb (Fig. 4A) 
and TNF- (Fig. 5A), both cytokines were modulated in terms of total amount. PDGF-bb (Fig. 4B) 
was reduced already at 3 months in deep sites only, while TNF- (Fig. 5B) also at moderate sites.  
After 3 and 6 months of treatment, levels of all cytokines were still higher than those of healthy 
control sites (p < 0.001). 
Correlation data between clinical parameters and inflammatory markers for which statistically 
significant differences were found at 6 months after non-surgical periodontal therapy in terms of total 
amount are shown in Table 3. IL-1 levels showed a significant and positive correlation with PD and 
GI at baseline (p < 0.05) and also at 6-month evaluation (p < 0.01). The amount of VEGF were 
significantly correlated with baseline PD and GI (p < 0.05) and with persistent inflammation (p < 
0.01) at 6 months. PDGF-bb was correlated with PD and GI at baseline (p < 0.001), and TNF- only 
with GI at baseline (p < 0.01). 
Discussion 
To the best of our knowledge this is the first study conducted in any population regarding the detection 
of VEGF, PDGF-bb and IL-9 in GCF of subjects with GAgP before and after non-surgical periodontal 
treatment. In the present investigation a multiplex bead immunoassay was employed to simultaneously 
measure the concentration of multiple biomarkers, whereas almost all previous studies used 
commercial immunoenzymatic assay (ELISA) kits to measure individual cytokine levels [10]. This 
new rapid and high sensitive/specific assay has so far not been used to assess the expression of these 
inflammatory mediators in GCF samples.   
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 10 
Our current understanding of factors, which may increase host susceptibility to periodontal tissue 
destruction by regulating individual response to chronic gingival inflammation in GAgP patients, is 
still incomplete [36]. Studies about periodontitis revealed that there is a relationship between increased 
number of blood vessels and progression of the disease [37, 38], In this scenario, VEGF and PDGF 
play a central role in regulating angiogenesis in inflammatory and wound healing process [16, 21]. 
VEGF is a multifunctional cytokine inducing proliferation of endothelial cells and increasing vascular 
permeability [17]. In spite of its frequent detection in periodontal tissues, data about its role in 
periodontal disease are limited and conflicting. In chronic periodontitis subjects the production of 
VEGF is upregulated in diseased sites if compared to healthy sites [18, 39, 40]. Its concentration 
increases proportionally with the severity of periodontal disease [18, 41] suggesting a role in the 
progression from gingivitis to periodontitis. On the contrary, a greater expression of VEGF was 
observed during the healing phase of periodontal disease [42]. 
In the present study, the GAgP patients were treated by quadrant-wise non-surgical periodontal 
treatment and strict plaque control measures were instituted. The improvements in clinical 
inflammatory and disease parameters were in line with those reported in the literature [43]. It is 
important to point out that plaque scores were maintained at a low level (<15%) through the study 
period, indicating both good oral hygiene performance of all patients and successful re-motivation 
during post-treatment controls. 
These clinical outcomes were accompanied by a statistically significant decrease in VEGF detection 
(pg and concentration) in both moderate and deep pocket sites. These results agree with those of 
previous studies in chronic periodontitis [18, 19] and may support the active pathological role of 
VEGF even in GAgP diseased sites. An intriguing finding from this study was the most pronounced 
decrease in VEGF content, in terms of total amount and concentration, in deep sites 3 months after 
treatment when compared to moderate sites. This finding well related to that reported by Pradeep et al. 
[18] and to the clinical demonstration that deep pockets experienced more PD reduction than moderate 
sites. The density of blood vessels increases with increasing PD [15].  
It is interesting that deep pocket sites experienced a statistically significant decrease in PDGF amounts 
after periodontal treatment. In contrast, no statistically significant changes were observed when 
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considering PDGF concentrations. Information in the literature on the role of PDGF in periodontal 
diseases is very limited and still debated. Previous studies demonstrated an enhanced expression in 
periodontal diseased sites in the rat model [44] and in the inflamed gingival tissue of periodontitis 
patients [45]. It is known that PDGF stimulates the secretion and production of collagenase by 
fibroblasts suggesting a potential role in the progression of periodontal disease [21, 22].  
Pro-inflammatory cytokines such as IL-1 and TNF- seem to play an important role in GAgP by 
controlling cellular interactions and functions [4]. When released in high concentration, they can 
stimulate the production of other inflammatory mediators (e.g. IL-6, prostaglandins, matrix 
metalloproteineases) involved in extracellular matrix connective tissue destruction and osteoclastic-
mediated bone loss, as well as up-regulate the production of angiogenic mediators [23, 24]. IL-1 and 
TNF- have been extensively studied in GCF of GAgP patients [8-10]. However, the effects of 
periodontal treatment on GCF levels of IL-1 are contraddictory. Some studies [12-14, 46] indicate 
that periodontal therapy reduces the GCF total amount of IL-1, suggesting a role for this cytokine in 
the disease process,
 
whereas others report no effect or an increase after periodontal treatment [47-49]. 
Here, IL-1 expression (pg and concentration) was markedly reduced in both moderate and deep 
pocket sites until 6 months following periodontal therapy and there was correlation between IL-1 and 
clinical parameters. Data from Engebretson et al. [47] and de Lima Oliveira et al. [14] support this 
observation, demonstrating that PD and CAL were each associated with increased GCF IL-1 levels. 
By contrast, we found an effect of mechanical periododontal therapy on GCF total amounts but not on 
GCF concentrations of TNF-. In agreement with the current data, a previous study observed that 
TNF- concentrations remained stable after mechanical periodontal therapy [14]. Bastos et al. [32] 
demonstrated that TNF- levels were elevated in GCF of both healthy and diseased sites from GAgP 
individuals, indicating that this mediator can be expressed in sites with different clinical status. The 
present data confirm the altered inflammatory response of GAgP subjects and suggest that TNF- may 
be a suitable indicator for periodontitis development.   
The levels of IL-9 had not been studied yet in GCF but its serum concentrations were found to be 
elevated in periodontitis patients compared to healthy individuals [31]. IL-9 has been described as a 
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pleiotropic cytokine, whose pro- or anti-inflammatory activities may significantly differ depending on 
the overall cytokine milieu [28]. Interestingly, the augment of IL-9 in inactive periapical lesions and a 
negative correlation with TNF- were recently described, suggesting a role of IL-9 in periapical lesion 
stability [29, 30]. In the present study, a different trend was observed when considering IL-9 GCF 
amount or concentration. While a significant elevation in IL-9 concentration was observed at moderate 
pocket sites 3 months after the completion of non-surgical periodontal therapy, its total amount was 
slightly decreased or fairly stable in moderate and deep pocket sites at 3- and 6-month evaluation. 
Further controlled studies with larger sample size may be useful to clarify the role of IL-9 in the 
etiopathogenesis of GAgP.  
Conclusions 
A significant decrease in the GCF levels of pro-inflammatory and angiogenic cytokines was observed 
in response to quadrant-wise non-surgical periodontal treatment, although they were still elevated 
when compared to healthy control group. Nevertheless, plaque control measures seem not to affect 
mediators such as IL-9 and partially PDGF-bb. These findings suggest a potential hyperreactivity of 
cells in these individuals that may favor periodontal tissue breakdown and a local inflammatory 
burden even with insignificant amount of bacterial plaque on teeth. The role of IL-9 on local 
periodontal destruction in these subjects requires further investigations. 
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Informed Consent Informed consent was obtained from all individual participants included in the 
study.  
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Table 1. Clinical parameters (mean ± SD) of GCF sampling sites over the experimental period in 
patients with GAgP and periodontally healthy controls 
 
 Healthy 
controls 
(n=15) 
GAgP subjects (n=16) 
  Moderate pocket sites (4-5 mm) 
 
Deep pocket sites (≥ 6 mm) 
 
  Baseline 3 months 6 months Baseline 3 months 6 months 
PI (%) 0 90.6 ± 20.2 9.4 ± 27.2*** 12.5 ± 28.9*** 93.8 ± 17.1 15.6 ± 23.9*** 21.9 ± 31.5*** 
GI 0 1.9 ± 0.5 0.5 ± 0.6*** 0.8 ± 0.8*** 2.5 ± 0.5¶ 0.8 ± 0.7*** 0.9 ± 0.8*** 
PD (mm) 1.6 ± 0.5 4.7 ± 0.5 3.3 ± 0.6*** 3.1 ± 0.8*** 8.8 ± 1.6§ 5.3 ± 1.1***§ 5.0 ± 1.8***§ 
CAL (mm) 1.6 ± 0.6 5.3 ± 0.8 4.2 ± 1.0*** 4.0 ± 1.0*** 9.4 ± 1.8§ 6.6 ± 0.9***§ 6.3 ± 1.1***§ 
GCF (µl) 0.21 ± 0.07 0.50 ± 0.35 0.27 ± 0.21*** 0.32 ± 0.16** 1.03 ± 0.34¶ 0.53 ± 0.36***¶ 0.58 ± 0.35***¶ 
GCF gingival crevicular fluid volume, GAgP generalized aggressive periodontitis, PI presence of plaque, GI 
gingival index, PD probing depth, CAL clinical attachment level, SD standard deviation. 
**P < 0.01 versus baseline. 
***P < 0.001 versus baseline.  
¶P < 0.01 versus moderate pocket sites. 
§P < 0.001 versus moderate pocket sites.  
 
 
 
 
 
Table 2. FMPS and FMBS over the experimental period in patients with GAgP and 
periodontally healthy controls 
 
 Healthy 
controls (n=15) 
GAgP subjects (n=16) 
  Baseline 3 months 6 months 
FMPS (%) 11.3 ± 2.7 37.3 ± 11.3 13.9 ± 4.7*** 14.9± 4.4*** 
FMBS (%) 7.9 ± 2.1 50.2 ± 13.9 18.1 ± 4.3*** 20.4 ± 6.1*** 
FMPS full-mouth plaque score, FMBS full-mouth bleeding score. 
***P < 0.001 versus baseline.  
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Table 3. Correlation between cytokines total amount (pg) in gingival crevicular fluid and clinical 
parameters at baseline and 6 months after periodontal therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GI  gingival index, PI presence of plaque, PD probing depth. 
*P <0.05,**P<0.01, ***P<0.001 
 
 
 
 
 
 
 
 
 
 
                Parameter Baseline 6 months after treatment 
IL-1ß  
 
  
GI 0.426* 0.533**  
PI               0.238                    0.254 
PD    0.589*** 0.512** 
VEGF    
GI    0.584** 0.502** 
PI 0.293 0.274 
PD   0.419* 0.319 
PDGF-bb   
GI 0.444* 0.127 
PI 0.321 0.136 
PD       0.635*** 0.115 
TNF-   
GI 0.402*.   0.285 
PI 0.212 0.324 
PD 0.264 0.297 
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Figure legends 
Fig. 1. Box-and-whisker plots showing the concentration (A) and total amount (B) of IL-1 in 
gingival crevicular fluid of periodontally healthy controls and subjects with aggressive periodontitis 
according to baseline PDs before and after non-surgical periodontal therapy. The box represents 
median, 25% and 75% percentiles, the whiskers represent data within 10% and 90% percentiles. 
*
P < 
0.05, ***P < 0.001.  
Fig. 2. Box-and-whisker plots showing the concentration (A) and total amount (B) of VEGF in 
gingival crevicular fluid of periodontally healthy controls and subjects with aggressive periodontitis 
according to baseline PDs before and after non-surgical periodontal therapy. The box represents 
median, 25% and 75% percentiles, the whiskers represent data within 10% and 90% percentiles.
 *
P < 
0.05, ***P < 0.001.  
Fig. 3. Box-and-whisker plots showing the concentration (A) and total amount (B) of IL-9 in gingival 
crevicular fluid of periodontally healthy controls and subjects with aggressive periodontitis according 
to baseline PDs before and after non-surgical periodontal therapy. The box represents median, 25% 
and 75% percentiles, the whiskers represent data within 10% and 90% percentiles.
*
P < 0.05.  
Fig. 4. Box-and-whisker plots showing the concentration (A) and total amount (B) of PDGF-bb in 
gingival crevicular fluid of periodontally healthy controls and subjects with aggressive periodontitis 
according to baseline PDs before and after non-surgical periodontal therapy. The box represents 
median, 25% and 75% percentiles, the whiskers represent data within 10% and 90% percentiles.
**
P < 
0.01, ***P < 0.001. 
Fig. 5. Box-and-whisker plots showing the concentration (A) and total amount (B) of TNF- in 
gingival crevicular fluid of periodontally healthy controls and subjects with aggressive periodontitis 
according to baseline PDs before and after non-surgical periodontal therapy. The box represents 
median, 25% and 75% percentiles, the whiskers represent data within 10% and 90% percentiles.
**
P < 
0.01, ***P < 0.001. 
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